At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

Patient advocate David Mitchell, 75, dies of multiple myeloma

David Mitchell, a tireless patient advocate whose lived experience with multiple myeloma shaped a decade of courageous leadership on behalf of patients nationwide, died Jan. 2. He was 75.

Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA

Rick Pazdur’s appointment as director of the FDA’s Center for Drug Evaluation and Research (CDER) comes at exactly the right moment, both for the agency and for the patients it serves.

Early endpoints are a balance of risk and benefit

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.

October 29, 2025

Vol.51 No.39

Regulatory News

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints

New research led by Friends of Cancer Research demonstrates that decreases in circulating tumor DNA after initiation of treatment are associated with improved overall survival in patients with advanced non-small cell lung cancer treated with immunotherapy or chemotherapy.

Monica Bertagnolli joins Friends of Cancer Research board of directors

Monica Bertagnolli, former director of NIH and NCI, joined the Friends of Cancer Research as board of directors.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Friends of Cancer Research announces publication focused on enhancing clinical trials with pragmatic trial elements

Friends of Cancer Research announced the publication of a commentary on the significance of pragmatic clinical trials in ESMO Real World Data and Digital Oncology.

September 13, 2024

Vol.50 No.34

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

YOU MAY BE INTERESTED IN

Patient advocate David Mitchell, 75, dies of multiple myeloma

Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA

Early endpoints are a balance of risk and benefit

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints

Monica Bertagnolli joins Friends of Cancer Research board of directors

Friends of Cancer Research announces publication focused on enhancing clinical trials with pragmatic trial elements

Renew today!

Subscriber content

Never miss an issue!

Login

At Friends meeting, data quality, modern evidence generation, and early regulatory alignment top the list of “next steps” for external control arms

YOU MAY BE INTERESTED IN

Patient advocate David Mitchell, 75, dies of multiple myeloma

Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA

Early endpoints are a balance of risk and benefit

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLCctMoniTR project aims to improve efficiency in development of intermediate endpoints

Monica Bertagnolli joins Friends of Cancer Research board of directors

Friends of Cancer Research announces publication focused on enhancing clinical trials with pragmatic trial elements

Never miss an issue!

Login

Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints